The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism

Free fatty acids (FFAs) play a pivotal role in metabolic control and cell signaling processes in various tissues. In particular, FFAs are known to augment glucose-stimulated insulin secretion by pancreatic beta cells, where fatty acid-derived metabolites, such as long-chain fatty acyl-CoAs, are beli...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 5; p. 152
Main Authors Tomita, Tsutomu, Hosoda, Kiminori, Fujikura, Junji, Inagaki, Nobuya, Nakao, Kazuwa
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 01.01.2014
Subjects
Endocrinology
FFAR1
GPR40
insulin secretion
LCFA
pancreatic beta cells
LCFA
pancreatic beta cells
FFAR1
GPR40
insulin secretion
Online AccessGet full text

Cover

More Information
Summary:Free fatty acids (FFAs) play a pivotal role in metabolic control and cell signaling processes in various tissues. In particular, FFAs are known to augment glucose-stimulated insulin secretion by pancreatic beta cells, where fatty acid-derived metabolites, such as long-chain fatty acyl-CoAs, are believed to act as crucial effectors. Recently, G-protein-coupled receptor 40 (GPR40), a receptor for long-chain fatty acids, was reported to be highly expressed in pancreatic beta cells and involved in the regulation of insulin secretion. Hence, GPR40 is considered to be a potential therapeutic target for the treatment of diabetes. In this review, we summarize the identification and gene expression patterns of GPR40 and its role in glucose metabolism. We also discuss the potential application of GPR40 as a therapeutic target.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Ikuo Kimura, Tokyo University of Agriculture and Technology, Japan
This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology.
Reviewed by: Carol Huang, University of Calgary, Canada; Kay Waud, Jones Institute for Reproductive Medicine, USA
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2014.00152